Literature DB >> 6307754

Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.

M Laburthe, B Amiranoff, N Boige, C Rouyer-Fessard, K Tatemoto, L Moroder.   

Abstract

GRF (10(-8) - 10(-5) M) is shown to inhibit competitively the binding of [125I]VIP to human and rat intestinal epithelial membranes. The affinity of GRF for VIP receptor is 700-800-times lower than that of VIP in both species. The order of affinity of different peptides is VIP greater than PHI greater than secretin greater than GRF in rat, and VIP greater than GRF greater than PHI greater than secretin in man. The important species specificity of VIP receptors in recognizing PHI and secretin does not occur in the case of GRF. GRF stimulates adenylate cyclase through its interaction with VIP receptors in rat and human membranes. However, while GRF behaves as a VIP agonist in human tissue, it is a partial agonist/antagonist of VIP in the rat.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6307754     DOI： 10.1016/0014-5793(83)80422-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  12 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  VIP receptors and control of short circuit current in the human intestinal clonal cell line Cl.19A.

Authors:  C Rouyer-Fessard; C Augeron; E Grasset; J J Maoret; C L Laboisse; M Laburthe
Journal:  Experientia       Date:  1989-12-01

3.  Intraepithelial lymphocytes, goblet cells and VIP-IR submucosal neurons of jejunum rats infected with Toxoplasma gondii.

Authors:  Débora M G Sant'Ana; Marcelo B Góis; Jacqueline N Zanoni; Aristeu V da Silva; Cleverton J T da Silva; Eduardo J A Araújo
Journal:  Int J Exp Pathol       Date:  2012-08       Impact factor: 1.925

4.  Growth hormone and prolactin responses to bolus and sustained infusions of GRH-1-40-OH in man.

Authors:  J A Goldman; M E Molitch; M O Thorner; W Vale; J Rivier; S Reichlin
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

5.  Growth-hormone releasing factor does not antagonize somatostatin effects on pancreatic and gastric secretions.

Authors:  M Chovet; M Dubrasquet; J Chariot; C Rozé
Journal:  Experientia       Date:  1985-11-15

6.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

7.  The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.

Authors:  A Couvineau; M Laburthe
Journal:  Biochem J       Date:  1985-01-15       Impact factor: 3.857

8.  Identification of glucagon receptors in rat brain.

Authors:  N M Hoosein; R S Gurd
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Vasoactive intestinal peptide stimulation of renal adenylate cyclase and antagonism by (4Cl-D-Phe6Leu17)VIP.

Authors:  N M Griffiths; N L Simmons; J Rivier
Journal:  Pflugers Arch       Date:  1989-06       Impact factor: 3.657

10.  Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.

Authors:  A Couvineau; M Rousset; M Laburthe
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.